Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market BioSpaceRegeneron's Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen's Sohonos.Rare DiseaseRead full story pharminent August 20, 2026 (Last updated: August 23, 2026) BioSpace Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos. Rare Disease Read full story Post navigation Previous: FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapyNext: Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026 Regulatory Trump nominates policy aide Overton to lead FDA pharminent August 19, 2026
